Clinical Trial

Microvascular Cardiac Allograft Vasculopathy Trial

Study acronym: mCAV
Unknown
View on ClinicalTrials.gov →
Record status
This record was last updated August 12, 2024 (before its estimated December 31, 2025 completion). Its status may not reflect the trial's current state.
Summary
The aim of the mCAV study is a comprehensive characterization of the genetic, morphological and functional phenotype of isolated microvascular graft vasculopathy (mCAV) after orthotopic heart transplantation (OHT). The utilized methods include dynamic echocardiography, magnetic resonance imaging, invasive microvascular resistance measurements, histology, cellular calcium-signaling and magnetocardiography as well as molecular genetic expression analysis (miRNA based).
Protocol Amendment History 1 change
critical Trial status changed: Recruiting → Unknown 2026-08-02
Trial Details
NCT Number NCT05826444
Lead Sponsor German Heart Institute
Collaborators: Deutsches Zentrum für Herz-Kreislauf-Forschung (DZHK), Deutsche Stiftung für Herzforschung
Conditions Cardiac Allograft Vasculopathy
Enrollment 50 participants
Start Date 2022-10-01
Primary Completion 2025-12-31 (estimated)
Study Completion 2025-12-31 (estimated)
Updated on ClinicalTrials.gov 2024-08-12